Vincent (Wenxin) Xu, MD , shows among patients with advanced kidney cancer on immunotherapy alone, KIM-1 reductions were seen in immune-inflamed tumors, while no KIM-1 drop was linked to immune-depleted tumors.
Related Presenters
Related Presenters